Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma

NCT07583810 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07583810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2026
Completion date
May 2, 2028
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

conjunctival mucosa-associated lymphoid tissue lymphoma, extranodal marginal zone lymphoma, gastric mucosa-associated lymphoid tissue lymphoma, lymphoma, marginal zone lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma